Cosentyx (secukinumab) is a prescription medication used to treat several autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the drug patent watch [1], Cosentyx is a biologic drug that was first approved by the FDA in 2015. The patent for Cosentyx is set to expire in 2035, and there are no generic versions available in the market yet.

The manufacturer of Cosentyx has released a statement regarding the use of this medication during the COVID-19 pandemic [2]. The statement mentions that there is currently no evidence to suggest that patients taking Cosentyx are at a higher risk of contracting COVID-19. However, it is essential to follow the CDC guidelines and take necessary precautions to reduce the risk of infection.

Like all medications, Cosentyx may cause side effects [3]. Some common side effects of Cosentyx include injection site reactions, upper respiratory tract infections, and diarrhea. Rare but severe side effects may include allergic reactions, infections, and malignancies. Patients taking Cosentyx should discuss any concerns they have with their healthcare provider.

In conclusion, Cosentyx is a prescription medication used to treat autoimmune diseases. While there is no evidence to suggest that patients taking Cosentyx are at a higher risk of contracting COVID-19, patients should take necessary precautions to reduce the risk of infection. As with all medications, patients taking Cosentyx should be aware of potential side effects and discuss any concerns with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/covid19
[3] https://www.mayoclinic.org/drugs-supplements/secukinumab-subcutaneous-route/side-effects/drg-20137344